Introduction Finding therapeutic alternatives to carbapenems in infections caused by extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) is imperative. Although fosfomycin was discovered more than 40 years ago, it was not investigated in accordance with current standards and so is not used in clinical practice except in...
-
May 16, 2017 (v1)PublicationUploaded on: March 25, 2023
-
May 11, 2020 (v1)Publication
Introduction Within the context of antimicrobial stewardship programmes, de-escalation of antimicrobial therapy is one of the proposed strategies for reducing the unnecessary use of broad-spectrum antibiotics (BSA). The empirical treatment of nosocomial and some healthcare- associated bloodstream infections (BSI) frequently includes a...
Uploaded on: December 4, 2022